About Calcium News

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted tentative approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Lilly’s osteoporosis treatment Evista® (Raloxifene Hydrochloride) Tablets, 60 mg.

This entry was posted on Monday, April 21st, 2008 at 4:13 am and is filed under Osteoporosis. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.